Research progress of nasal mucosal immunization vaccine against COVID-19

WU Yaqi; LI Meng; XING Haonan; CHEN Daquan; ZHENG Aiping

doi:10.11665/j.issn.1000-5048.20220602

Journal of China Pharmaceutical University > 2022 > 53(6): 643-650. > DOI: 10.11665/j.issn.1000-5048.20220602

WU Yaqi, LI Meng, XING Haonan, CHEN Daquan, ZHENG Aiping. Research progress of nasal mucosal immunization vaccine against COVID-19[J]. Journal of China Pharmaceutical University, 2022, 53(6): 643-650. DOI: 10.11665/j.issn.1000-5048.20220602

Citation:

PDF (1230 KB)

Research progress of nasal mucosal immunization vaccine against COVID-19

1.
School of Pharmacy, Yantai University, Yantai 264005
2.
Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing 100850, China

More Information

Received Date: October 17, 2022
Revised Date: December 15, 2022

Graphical Abstract

Abstract

Abstract

Respiratory mucosal immune system is the body's first line of defense against infection.Since the outbreak of novel coronavirus disease 2019 (COVID-19) in 2019,nasal mucosal immune vaccine, with its ability to induce cellular, humoral and mucosal triple immune responses, has become a research hotspot.This article focuses on novel coronavirus, with an understanding of its structure and pathogenesis, a brief introduction to the immune mechanism of nasal mucosa, a summary of the different types of nasal mucosal immune vaccines and their clinical research, aiming to provide some theoretical reference for the development of new vaccines, and exploration of the best methods and strategies to combat COVID-19.
- COVID-19,
- SARS-CoV-2,
- respiratory infection,
- nasal mucosal immune vaccine,
- triple immunity

FullText(HTML)

References (50)

References

[1]	. Am J Prev Med，2022，63（6）：1062-1063.
[2]	Primorac D，Vrdoljak K，Brlek P，et al. Adaptive immune responses and immunity to SARS-CoV-2［J］. Front Immunol，2022，13：848582.
[3]	Tang XL，Wu CC，Li X，et al. On the origin and continuing evolution of SARS-CoV-2［J］. Natl Sci Rev，2020，7（6）：1012-1023.
[4]	Kang SS，Yang M，Hong ZS，et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites［J］. Acta Pharm Sin B，2020，10（7）：1228-1238.
[5]	Letko M，Marzi A，Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses［J］. Nat Microbiol，2020，5（4）：562-569.
[6]	Wu CR，Liu Y，Yang YY，et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods［J］. Acta Pharm Sin B，2020，10（5）：766-788.
[7]	Jackson CB，Farzan M，Chen B，et al. Mechanisms of SARS-CoV-2 entry into cells［J］.Nat Rev Mol Cell Biol，2022，23（1）：3-20.
[8]	HouYJ，Okuda K，Edwards CE，et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract［J］. Cell，2020，182（2）：429-446.e14.
[9]	Takabayashi T，Yoshida K，Imoto Y，et al. Regulation of the expression of SARS-CoV-2 receptor angiotensin-converting enzyme 2 in nasal mucosa［J］. Am J Rhinol Allergy，2022，36（1）：115-122.
[10]	Nocini R，Henry BM，Mattiuzzi C，et al. Improving nasal protection for preventing SARS-CoV-2 infection［J］. Biomedicines，2022，10（11）：2966.
[11]	McGhee JR，Mestecky J，Dertzbaugh MT，et al. The mucosal immune system：from fundamental concepts to vaccine development［J］. Vaccine，1992，10（2）：75-88.
[12]	Ryan EJ，Daly LM，Mills KH. Immunomodulators and delivery systems for vaccination by mucosal routes［J］. Trends Biotechnol，2001，19（8）：293-304.
[13]	Davis SS. Nasal vaccines［J］. Adv Drug Deliv Rev，2001，51（1/2/3）：21-42.
[14]	Woodrow KA，Bennett KM，Lo DD. Mucosal vaccine design and delivery［J］. Annu Rev Biomed Eng，2012，14：17-46.
[15]	Focosi D，Maggi F，Casadevall A. Mucosal vaccines，sterilizing immunity，and the future of SARS-CoV-2 virulence［J］. Viruses，2022，14（2）：187.
[16]	Zaman M，Chandrudu S，Toth I. Strategies for intranasal delivery of vaccines［J］. Drug Deliv Transl Res，2013，3（1）：100-109.
[17]	Bernasconi V，Norling K，Bally M，et al. Mucosal vaccine development based on liposome technology［J］. J Immunol Res，2016，2016：5482087.
[18]	Tiboni M，Casettari L，Illum L. Nasal vaccination against SARS-CoV-2：synergistic or alternative to intramuscular vaccines［J］？ Int J Pharm，2021，603：120686.
[19]	Zainutdinov SS，Sivolobova GF，Loktev VB，et al. Mucosal immunity and vaccines against viral infections［J］. VoprVirusol，2022，66（6）：399-408.
[20]	Cyranoski D. Profile of a killer：the complex biology powering the coronavirus pandemic［J］. Nature，2020，581（7806）：22-26.
[21]	Ahn JH，Kim J，Hong SP，et al. Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19［J］. J Clin Invest，2021，131（13）：e148517.
[22]	Hassan AO，Kafai NM，Dmitriev IP，et al. A single-dose intranasal ChAdvaccine protects upper and lower respiratory tracts against SARS-CoV-2［J］. Cell，2020，183（1）：169-184.e13.
[23]	Tang J，Cai L，Xu CF，et al. Nanotechnologies in delivery of DNA and mRNA vaccines to the nasal and pulmonary mucosa［J］. Nanomaterials （Basel），2022，12（2）：226.
[24]	Ingolotti M，Kawalekar O，Shedlock DJ，et al. DNA vaccines for targeting bacterial infections［J］. Expert Rev Vaccines，2010，9（7）：747-763.
[25]	Xu YY，Yuen PW，Lam JKW. Intranasal DNA vaccine for protection against respiratory infectious diseases：the delivery perspectives［J］. Pharmaceutics，2014，6（3）：378-415.
[26]	Mallapaty S，Callaway E. What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine［J］. Nature，2021，592（7852）：15-17.
[27]	Sheridan C. First COVID-19 DNA vaccine approved，others in hot pursuit［J］. Nat Biotechnol，2021，39（12）：1479-1482.
[28]	Mallapaty S. India's DNA COVID vaccine is a world first - more are coming［J］. Nature，2021，597（7875）：161-162.
[29]	University of Eastern Finland.University of Eastern Finland scientists are developing nasal vaccine against COVID-19［EB/OL］.（2020-04-15）［2020-04-21］.https：//sciencebusiness.net/network-updates/university-eastern-finland-scientists-are-developing-nasal-vaccine-against-covid-19.
[30]	Boroumand H，Badie F，Mazaheri S，et al. Chitosan-based nanoparticles against viral infections［J］. Front Cell Infect Microbiol，2021，11：643953.
[31]	Mura P，Maestrelli F，Cirri M，et al. Multiple roles of chitosan in mucosal drug delivery：an updated review［J］. Mar Drugs，2022，20（5）：335.
[32]	Gong X，Gao Y，Shu J，et al. Chitosan-based nanomaterial as immune adjuvant and delivery carrier for vaccines［J］. Vaccines （Basel），2022，10（11）：1906.
[33]	Kumar US，Afjei R，Ferrara K，et al. Gold-nanostar-chitosan-mediated delivery of SARS-CoV-2 DNA vaccine for respiratory mucosal immunization：development and proof-of-principle［J］. ACS Nano，2021，15（11）：17582-17601.
[34]	Brito LA，Kommareddy S，Maione D，et al. Self-amplifying mRNA vaccines［J］. Adv Genet，2015，89：179-233.
[35]	Vogel AB，Kanevsky I，Che Y，et al. A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates［J］. bioRxiv，2020.DOI：10.1101/2020.09.08.280818.
[36]	Tang JY，Zeng C，Cox TM，et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination［J］. Sci Immunol，2022，7（76）：eadd4853.
[37]	Amyris，Inc.Amyris achieves promising in-vivo results for intranasal delivery of RNA/NLC Vaccine［EB/OL］.［2021-08-20］.https：//www.prnewswire.com/news-releases/amyris-achieves-promising-in-vivo-results-for-intranasal-delivery-of-rnanlc-vaccine-301359641.html.
[38]	Rollier CS，Reyes-Sandoval A，Cottingham MG，et al. Viral vectors as vaccine platforms：deployment in sight［J］. Curr Opin Immunol，2011，23（3）：377-382.
[39]	Ohtsuka J，Fukumura M，Furuyama W，et al. A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector［J］. Sci Rep，2019，9（1）：12901.
[40]	Ohtsuka J，Imai M，Fukumura M，et al. Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2［J］. iScience，2021，24（12）：103379.
[41]	Park JG，Oladunni FS，Rohaim MA，et al. Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2［J］. iScience，2021，24（9）：102941.
[42]	Qin X，Li S，Li X，et al. Development of an Adeno-Associated Virus-Vectored SARS-CoV-2 Vaccine and Its Immunogenicity in Mice［J］. Front Cell Infect Microbiol，2022，12：802147.
[43]	TWJrDubensky，Kanne DB，Leong ML. Rationale，progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants［J］. Ther Adv Vaccines，2013，1（4）：131-143.
[44]	An XY，Martinez-Paniagua M，Rezvan A，et al. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2［J］. iScience，2021，24（9）：103037.
[45]	Du YY，Xu YH，Feng J，et al. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse［J］. Vaccine，2021，39（16）：2280-2287.
[46]	Graham BS. Rapid COVID-19 vaccine development［J］. Science，2020，368（6494）：945-946.
[47]	Alu AQ，Chen L，Lei H，et al. Intranasal COVID-19 vaccines：from bench to bed［J］. EBioMedicine，2022，76：103841.
[48]	IndexNature. Inhalable vaccine in trials［EB/OL］.［2022-11-30］. https：//www.nature.com/articles/d42473-022-00043-y.
[49]	Halperin SA，Ye L，MacKinnon-Cameron D，et al.Final efficacy analysis，interim safety analysis，and immunogenicity of a single dose of recombinant novel coronavirus vaccine （adenovirus type 5 vector） in adults 18 years and older：an international，multicentre，randomised，double-blinded，placebo-controlled phase 3 trial［J］.Lancet，2022，399（10321）：237-248.
[50]	Bo XZ.Wantai Biology：Nasal spray influenza virus vector COVID-19 vaccine is included in emergency use［EB/OL］.2022-12-06］.https：//news.sina.com.cn/s/2022-12-06/doc-imqmmthc7176550.shtml.

Cited By

Get Citation

PDF

XML

Article views (380) PDF downloads (757)

Turn off MathJax

Article Contents

Abstract

References

Research progress of nasal mucosal immunization vaccine against COVID-19

Abstract

References

Catalog

Export File

Citation

Format

Content